XENE Key Statistics, Chart & Performance
The current stock price of XENE is 43.6 USD. In the past month the price increased by 6.97%. In the past year, price increased by 12.87%.
XENE Latest News, Press Relases and Analysis
XENE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B |
Related stock screener links
About XENE
Company Profile
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Company Info
XENON PHARMACEUTICALS INC
3650 Gilmore Way
Vancouver BRITISH COLUMBIA V5G 48W CA
CEO: Simon Pimstone
Employees: 316
Phone: 16044843300
XENON PHARMACEUTICALS INC / XENE FAQ
What does XENON PHARMACEUTICALS INC do?
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
What is the current price of XENE stock?
The current stock price of XENE is 43.6 USD. The price decreased by -1.04% in the last trading session.
Does XENE stock pay dividends?
XENE does not pay a dividend.
What is the ChartMill rating of XENON PHARMACEUTICALS INC stock?
XENE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for XENE stock?
XENON PHARMACEUTICALS INC (XENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.89).
What is the market capitalization of XENE stock?
XENON PHARMACEUTICALS INC (XENE) has a market capitalization of 3.37B USD. This makes XENE a Mid Cap stock.
XENE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to XENE. When comparing the yearly performance of all stocks, XENE is one of the better performing stocks in the market, outperforming 79.4% of all stocks.
XENE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XENE. No worries on liquidiy or solvency for XENE as it has an excellent financial health rating, but there are worries on the profitability.
XENE Financial Highlights
Over the last trailing twelve months XENE reported a non-GAAP Earnings per Share(EPS) of -3.89. The EPS decreased by -37.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.4% | ||
| ROE | -54.75% | ||
| Debt/Equity | 0 |
XENE Forecast & Estimates
26 analysts have analysed XENE and the average price target is 56.19 USD. This implies a price increase of 28.86% is expected in the next year compared to the current price of 43.6.
For the next year, analysts expect an EPS growth of -43.23% and a revenue growth 2460.65% for XENE